MedTrace Logo

Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

NCT03157830 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to assess the efficacy of Ocrelizumab (OCR) in Relapsing Multiple Sclerosis patients who have been previously treated with natalizumab (NTZ) by evaluating relapse rate, progression on MRI and disability progression.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Kyle Smoot, MD · Providence Brain & Spine Institute

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2022-01-28
Completion
2022-06-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03157830 on ClinicalTrials.gov